Results from the Phase 2 POLAR Trial: Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer

oncodaily - Pancreatic cancer remains one of the most challenging malignancies to treat, particularly in the metastatic setting, where immunotherapy has historically shown minimal activity. However, a biologically defined subset of patients […]

AI Summary: The Phase 2 POLAR trial presented results evaluating pembrolizumab combined with olaparib in homologous recombination–deficient metastatic pancreatic cancer, including safety, response rates and biomarker analyses. Investigators observed signals of activity in HRD‑selected patients, suggesting the immunotherapy–PARP inhibitor combination merits larger randomized testing rather than immediate headline glory.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 3 hrs

New drug doubles one-year survival in metastatic pancreatic cancer / 6 wks

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 46 hrs

Common asthma drug may overcome immunotherapy resistance in cancers / 11 days

Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days

Zoldonrasib shows durable responses in KRAS G12D lung cancer / 5 wks

James P. Allison wins AACR lifetime achievement award / 7 wks